Insuman Comb 15 Solostar

Insulin human, the active ingredient in Insuman Comb 15 Solostar, is an insulin presented as a solution for injection for subcutaneous use. It is used to treat diabetes mellitus type 1 and type 2 by replacing deficient endogenous insulin.

GNH USA supplies Insuman Comb 15 Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global demand. Its distribution network includes major hospital pharmacies and procurement agencies across Europe, Asia and the Americas.

Insuman Comb 15 Solostar is an insulin preparation used in the management of diabetes mellitus.

Type 1 Diabetes: provides basal and prandial insulin coverage to achieve glycemic control. Type 2 Diabetes: supplements endogenous insulin to improve blood glucose levels when diet, exercise, and oral agents are insufficient. Diabetic Ketoacidosis (adjunctive therapy): supplies exogenous insulin to reduce hyperglycemia and halt ketone production. Gestational Diabetes (under specialist guidance): helps maintain target glucose levels during pregnancy.

Insuman Comb 15 Solostar may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Hypoglycemia: symptoms such as sweating, tremor, and confusion due to low blood glucose. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with improved glycemic control.

Serious or Rare Side Effects: - Severe hypoglycemia: loss of consciousness or seizures requiring emergency treatment. - Anaphylaxis: life‑threatening allergic reaction with airway compromise. - Insulin antibodies: formation of antibodies that may alter insulin action.

When using Insuman Comb 15 Solostar, several precautions should be observed. - Dose individualization: adjust dosage based on frequent blood glucose monitoring and clinical response. - Hypoglycemia risk: educate patients to recognize and treat low glucose promptly. - Renal impairment: monitor kidney function as reduced clearance may increase insulin effect. - Pregnancy and lactation: use only if benefits outweigh potential risks to mother and fetus. - Drug interactions: review concomitant medications that may potentiate or diminish insulin action. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 15 Solostar can interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Concurrent sulfonylureas: additive hypoglycemic effect may cause severe low blood glucose. - Beta‑blockers: may mask typical hypoglycemia symptoms, complicating detection. - MAO inhibitors: potential for enhanced insulin‑mediated glucose reduction.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may increase insulin sensitivity, requiring dose adjustment. - Thiazide diuretics: can raise blood glucose, possibly reducing insulin efficacy. - Corticosteroids: may increase insulin requirements due to hyperglycemic effect.